AUSTIN, Texas, June 12, 2025--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that ...

The Serum Amyloid A (SAA) proteins constitute a family of acute‐phase reactants whose expression is dramatically upregulated in response to inflammatory stimuli. Historically linked to amyloid ...

AUSTIN, Texas — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial ...

ImmunoPrecise Antibodies Ltd., a leader in AI-powered drug discovery and biotherapeutics, today announced compelling in vitro results demonstrating that its artificial intelligence- designed GLP-1 ...

Five rationally engineered peptide sequences—AI-optimized for improved stability and peptidase resistance—were tested against benchmark GLP-1 analogs in receptor activation assays.

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor Provided by GlobeNewswire Jun 15, 2025, 4:45:00 AM ...

In this Case Study, the authors describe paraneoplastic psychosis and catatonia in a patient with encephalitis associated with an immature teratoma of the ovary and NMDA receptor antibodies.

Five rationally engineered peptide sequences—AI-optimized for improved stability and peptidase resistance—were tested against benchmark GLP-1 analogs in receptor activation assays. Two lead candidates ...

The chemokine receptor CXCR7 is an atypical CXCL12 receptor that, as opposed to the classical CXCL12 receptor CXCR4, signals preferentially via the β-arrestin pathway and does not mediate chemotaxis.

BACKGROUND: GLP-1RAs (glucagon-like peptide-1 receptor agonists) have consistently demonstrated a protective effect against ischemic stroke. However, whether this benefit also extends to nontraumatic ...